Skip to main content
. Author manuscript; available in PMC: 2013 Mar 18.
Published in final edited form as: Mol Cancer Ther. 2009 Jan;8(1):178–184. doi: 10.1158/1535-7163.MCT-08-0643

Figure 4.

Figure 4

Effects of gp120-IIIB treatment on prostate tumor growth. Male severe combined immunodeficient mice were subcutaneously challenged in the right bilateral flank with 2 × 106 PC3 or DU145 cells in 100 µL serum-free RPMI 1640. Tumors were allowed to reach 500 mm3 in size. Subsequently, tumor-bearing mice received 100 ng/mL gp120-IIIB in PBS or 100 ng/mL BSA in PBS by intraperitoneal injection every 3 d. Mean ± SE percentage change in tumor size from day 0 was measured using a Thorpe engineer’s caliper from three separate experiments with experimental groups containing five mice each. ★, P < 0.01, statistical significance between gp120-IIIB-treated and control groups.